MedWatch

Series of setbacks have not caused Orphazyme CEO to consider departing

Even though much has happened in the four months in which Christophe Bourdon has sat in the main seat at Orphazyme, the newly-minted CEO is determined to seek opportunities in NPC. He does not have a lot to say on where he sees himself in a year.

Orphazyme CEO Christophe Bourdon | Photo: Orphazyme / PR

A lot has happened since Christophe Bourdon was appointed the head of Orphazyme back in early March. In spite of a series of consecutive disappointments, the CEO does not plan to seek other opportunities than the one he currently has as the chief of the Copenhagen-based biotech company, he tells MedWatch.

Following Friday's discouraging announcement that the US Food And Drug Administration (FDA) has given a complete response letter in which it rejects the company's main candidate arimoclomol for treating the metabolic disorder Niemann-Pick type C (NPC)

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs